Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Exec Frets over Material Cost Surge amid Middle East Crisis
Kenshi Kinoshita, director general of the Japan Pharmaceutical Manufacturers Association (JPMA), said on April 16 that escalating tensions in the Middle East have yet to have an immediate impact on drug supply, but are already pushing up raw material costs.…
To read the full story
Related Article
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
ORGANIZATION
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…